Balancing the benefits and risks of drug treatment: A stated-preference, discrete choice experiment with patients with psoriasis

Archives of Dermatology

Volumn 143, Issue 9, 2007, Pages 1175-1179

  Seston, Elizabeth M ^a   Ashcroft, Darren M ^a   Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSORIASIS AGENT;

ADULT; AGED; ARTICLE; BOOTSTRAPPING; CANCER RISK; DISEASE DURATION; DRUG INDICATION; FEMALE; HEALTH CARE; HEALTH CARE QUALITY; HUMAN; HYPERTENSION; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; QUESTIONNAIRE; RELAPSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SKIN CANCER; SKIN IRRITATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; PSORIASIS; QUESTIONNAIRES; RISK FACTORS;

EID: 34548852889     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.9.1175     Document Type: Article

References (32)

1. Nevitt GJ, Hutchinson PE. Psoriasis in the community: prevalence, severity and patients' beliefs and attitudes towards the disease. Br J Dermatol. 1996;135(4):533-537.
2. Ramsay B, O'Reagan M. A survey of the social and psychological effects of psoriasis. Br J Dermatol. 1988;118(2):195-201.
3. Fried RG, Friedman S, Paradis C, et al. Trivial or terrible? the psychosocial impact of psoriasis. Int J Dermatol. 1995;34(2):101-105.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3, pt 1):401-407.
5. Jowett S, Ryan T. Skin disease and handicap: an analysis of the impact of skin conditions. Soc Sci Med. 1985;20(4):425-429.
6. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol. 1989;20(1):53-63.
7. Feldman SR, Fleischer AB, Reboussin DM, Rapp SR, Bradhaam DD, Exum ML. The economic impact of psoriasis increases with psoriasis severity. J Am Acad Dermatol. 1997;37(4):564-569.
8. Fairhurst DA, Ashcroft DM, Griffiths CEM. Optimal management of severe plaque form of psoriasis. Am J Clin Dermatol. 2005;6(5):283-294.
9. Richards HL, Fortune DG, Griffiths CEM. Adherence to treatment in patients with psoriasis. J Eur Acad Dermatol Venereol. 2006;20(4):370-379.
10. van de Kerkhof PC, De Hoop D, de Korte J, Cobolens SA, Kuipers MV. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology. 2000;200(4):292-298.
11. Zaghoul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140(4):408-414.
12. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life. Arch Dermatol. 2001;137(3):280-284.
13. Nijsten T, Rolstad T, Feldman SR, Stern RS. Members of the National Psoriasis Foundation: more extensive disease and better informed about treatment options. Arch Dermatol. 2005;141(1):19-26.
14. Jemec GB, Wulf HC. Patient-physician consensus on quality of life in dermatology. Clin Exp Dermatol. 1996;21(3):177-179.
15. Hermansen SE, Helland CA, Finlay AY. Patients' and doctors' assessment of skin disease handicap. Clin Exp Dermatol. 2002;27(3):249-250.
16. Ryan M, Gerard K. Using discrete choice experiments to value health care programmes. Appl Health Econ Health Policy. 2003;2(1):55-64.
17. Griffiths CEM, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Technol Assess. 2000;4(40):1-125.
18. Ashcroft DM, Li Wan Po AL, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ. 2000;320(7240):963-970.
19. Ho VC, Griffiths CEM, Albrecht G, et al; PISCES Study Group. Intermittent short courses of cyclosporin (Neoral®) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. Br J Dermatol. 1999;141(2):283-291.
20. Van Dooren-Greebe RJ, Kuijpers Al, Mulder J, De Boo T, Van de Kerkhof PC. Methotrexate revisited. Br J Dermatol. 1994;130(2):204-210.
21. Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested cohort crossover study. Lancet. 2001;358(9287):1042-1045.
22. Gordon KB, Feldman SR, Koo J, Menter A, Rolstad T, Krueger G. Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol. 2005;141(1):82-84.
23. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger G. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50(6):859-866.
24. Street DJ, Burgess L, Louviere JJ. Quick and easy choice sets: constructing optimal and nearly optimal stated choice experiments. Int J Res Mark. 2005;22:459-470.
25. Feldman SR, Fleischer AB, Reboussin DM, et al. The Self-Administered Psoriasis Area and Severity Index is valid and reliable. J Invest Dermatol. 1996;106(1):183-186.
26. Greene WH. Models with discrete dependent variables. In: Greene WH, ed. Econometric Analysis. 4th ed. Upper Saddle River, NJ: Prentice Hall; 2000:811-896.
27. Small KA, Rosen HS. Applied welfare economics with discrete choice models. Econometrica. 1981;49:105-130.
28. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. New York, NY: Chapman & Hall; 1994:168-176.
29. Scott A. Identifying and analysing dominant preferences in discrete choice experiments: an application in health care. J Econ Psychol. 2002;23:383-398.
30. Fraenkel L, Bogardus ST, Concato J, Felson DT. Unwillingness of rheumatoid arthritis patients to risk adverse effects. Rheumatology (Oxford). 2002;41(3):253-261.
31. Berry DC, Bradlow A, Bersellini E. Perceptions of the risks and benefits of medicines in patients with rheumatoid arthritis and other painful musculoskeletal conditions. Rheumatology (Oxford). 2004;43(7):901-905.
32. Fraenkel L, Bogardus ST, Concato J, Felson DT, Wittink DR. Patient preferences for the treatment of rheumatoid arthritis. Ann Rheum Dis. 2004;63(11):1372-1378.